Clinical bottom line
SGLT2 inhibitors have emerged as a promising therapeutic option for patients with heart failure with preserved ejection fraction (HFpEF), including those without diabetes. Recent evidence demonstrates modest but consistent benefits in reducing heart failure hospitalizations and improving symptoms in non-diabetic HFpEF populations. However, their role in primary care requires careful patient selection and monitoring, as data on long-term outcomes and mortality benefits remain limited.
What the evidence shows
HFpEF accounts for approximately half of heart failure cases and has historically lacked effective disease-modifying treatments. SGLT2 inhibitors, initially developed for glycemic control in diabetes, have shown cardiovascular benefits beyond glucose lowering.
The EMPEROR-Preserved trial, summarized by Wagdy et al. (2021), was a landmark study demonstrating that empagliflozin reduced the composite endpoint of cardiovascular death or heart failure hospitalization in patients with HFpEF, including a substantial subgroup without diabetes. This trial shifted the paradigm by establishing SGLT2 inhibitors as a treatment option in HFpEF irrespective of diabetic status.
Jhund et al. (2022) reviewed mechanisms by which SGLT2 inhibitors may benefit HFpEF patients, including diuretic effects, improved myocardial energetics, and reduced inflammation and fibrosis. These pleiotropic effects support their use in non-diabetic HFpEF, where metabolic dysfunction contributes to pathophysiology.
Faluk et al. (2024) provide a contemporary synthesis of clinical trial data, confirming that SGLT2 inhibitors improve patient-reported outcomes and reduce heart failure hospitalizations in non-diabetic HFpEF cohorts. However, mortality benefits remain uncertain, with some trials showing neutral effects on all-cause death.
Clemmer et al. (2023) conducted a retrospective analysis in real-world settings, affirming the safety and effectiveness of SGLT2 inhibitors in diverse HFpEF populations, including those managed in primary care. Their findings suggest that early initiation may improve clinical trajectories.
Echouffo-Tcheugui et al. (2021) propose that HFpEF is a metabolic disorder amenable to therapies targeting systemic and myocardial metabolism, further rationalizing SGLT2 inhibitor use beyond diabetic patients.
Caveats and uncertainty
While SGLT2 inhibitors reduce heart failure hospitalizations, their impact on mortality in non-diabetic HFpEF remains unclear, necessitating cautious interpretation.
Most evidence derives from large trials with selected populations; applicability to frail elderly or those with multiple comorbidities common in primary care may be limited.
Potential adverse effects such as volume depletion, genitourinary infections, and rare ketoacidosis require vigilance, especially in non-diabetic patients.
Optimal timing, dosing, and combination with other HFpEF therapies are not fully established. Long-term safety data in non-diabetic HFpEF are still emerging.
Heterogeneity of HFpEF phenotypes may influence treatment response, and biomarkers to identify likely responders are lacking.
How this may change practice
Primary care clinicians should consider SGLT2 inhibitors for patients with symptomatic HFpEF regardless of diabetes status, particularly to reduce hospitalization risk.
Baseline renal function and volume status should be assessed before initiation, with ongoing monitoring for adverse events.
Patient education on potential side effects and adherence is critical to maximize benefits.
Integration of SGLT2 inhibitors into HFpEF management may complement existing therapies such as blood pressure control and lifestyle modification.
Referral to cardiology may be warranted for complex cases or uncertain diagnoses.
Future guidelines are expected to incorporate SGLT2 inhibitors as standard care for non-diabetic HFpEF, reinforcing their role in primary care.